drugset / Trial / NCT02308332

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

NCT02308332 ↗

Phase 4 Completed 58 enrolled UMC Utrecht Gilead Sciences · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will evaluate the effects of switching Atripla to Eviplera on neurocognition measured by neuropsychological testing and functional MRI

Timeline

Start
2015-02
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eviplera Unknown — —

Indications